Integrative analysis of data from The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC), utilizing the oncoPredict R package (29), revealed that patients with breast cancer with MTAP homologous deletion exhibited heightened sensitivity to chemotherapeutic agents, particularly PARPi (Figure 2A). This evidence concerns the gene MTAP and breast cancer.